Amneal Pharmaceuticals (AMRX) reported Q3 adjusted earnings Friday of $0.16 per diluted share, down from $0.19 a year earlier.
Four analysts polled by Capital IQ expected $0.14.
Net revenue for the quarter ended Sept. 30 was $702.5 million, up from $620 million a year earlier.
Three analysts polled by Capital IQ expected $693.7 million.
For 2024, the company continues to expect adjusted EPS of $0.57 to $0.63. Four analysts surveyed by Capital IQ expected $0.60.
Full-year net revenue is projected to be $2.70 billion to $2.80 billion. Three analysts polled by Capital IQ expect $2.75 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments